We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02250443
Previous Study | Return to List | Next Study

Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis (BYM338)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02250443
First Posted: September 26, 2014
Last Update Posted: October 12, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
  Purpose
This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM was demonstrated after a single 30 mg/kg i.v. dose of BYM338. This study is designed to confirm the efficacy, safety and tolerability of BYM338 in sIBM with long-term dosing.

Condition Intervention Phase
Sporadic Inclusion Body Myositis (sIBM) Drug: BYM338 (Bimagrumab) Phase 2 Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Long-Term Safety & Tolerability [ Time Frame: Approx. 3 Years ]
    This is a non-confirmatory, multicenter, open-label, non-randomized trial which will extend active treatment to those patients that participated in the preceding proof-of-concept study (CBYM338X2205) in order to collect long-term safety and tolerability data. Safety assessments will be performed at each site visit and will include physical examinations, ECGs, vital signs, standard clinical laboratory evaluations (hematology, blood chemistry, urinalysis) adverse event and serious adverse event monitoring of 14 patients will be evaluated.


Secondary Outcome Measures:
  • Changes in lean body mass from baseline [ Time Frame: Baseline, Week 8, 16, 24, 52, 76, 104, 132, 160 of Treatment ]
    To assess the effect of multiple doses of BYM338 on lean body mass as measured by DXA in terms of change from baseline.

  • Collect pharmacokinetic data from multiple i.v. dosing [ Time Frame: Pre-dose, 30 mins & 4 hours post-dose on Day 1. Pre-dose only on each subsequent administration ]
    To obtain pharmacokinetic data from multiple i.v. dosing of BYM338 in this patient population.

  • Changes in physical function reported by patients [ Time Frame: Baseline, Weeks 16, 24, 52, 76, 104 of Treatment ]
    - To assess the effect of BYM338 on physical function reported by patients as measured by the sIBM Functional Assessment (sIFA) in terms of change from baseline

  • Changes in muscle strength from baseline. [ Time Frame: Baseline, Weeks 16, 24, 52, 76, 104, 132, 160 of Treatment ]
    - To assess the effect of BYM338 in muscle strength by Quantitative Muscle Testing (QMT) in patients with sIBM in terms of change from baseline.

  • Changes in muscle function from baseline. [ Time Frame: Screening, Baseline, Weeks 16, 24, 52, 76, 104, 132, 160 of Treatment ]
    - To assess the effect of BYM338 on additional muscle function measures (hand-grip and pinch-grip dynamometry and 6 minute walking tests) in terms of change from baseline.

  • Changes in thigh muscle volume from baseline [ Time Frame: Baseline, Weeks 8 & 16 of Treatment ]
    - To assess the effect of BYM338 on thigh muscle volume by MRI in terms of change from baseline.


Enrollment: 10
Study Start Date: March 2014
Study Completion Date: August 2016
Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BYM338
BYM338 Group
Drug: BYM338 (Bimagrumab)

Detailed Description:
This is a non-confirmatory, multicenter, open-label, non-randomized trial which will extend active treatment to those patients that participated in the preceding proof-of-concept study (CBYM338X2205) in order to collect long-term safety and tolerability data. Up to 14 patients with sIBM will be invited to enroll into the study to receive BYM338 open-label for a period of approximately 3 years or until BYM338 is commercially available, whichever comes first. The study consists of a maximum 28-day screening period, a 5-day baseline period, and a treatment period consisting of the site visits at 4-week intervals for treatment administration, safety and pharmacokinetic follow-up. All patients will be administered a medium level i.v. BYM338 dose regardless of their treatment allocation in the prior study.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent must be obtained before any assessment is performed.
  • Patients who participated in the CBYM338X2205 study. A patient is defined as participating in the study if they were enrolled and received study medication.
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion Criteria:

  • Patients for whom the treating physician considers it inappropriate for continuation into the study, including consideration of physical and laboratory assessment of the patient at screening.
  • Patients who were non-compliant or demonstrated a serious protocol deviation in the previous study.
  • Use of other investigational drugs at the time of enrollment, within 30 days or 5 half-lives of enrollment, or until the expected PD effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  • History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
  • Swallowing difficulty or other reason that precludes adequate intake of energy and protein, defined as at least 20 kcal/kg/day and 0.6 g protein/kg/day as determined by the investigators assessment.
  • On the Columbia-Suicide Severity Rating Scale, a score of 4 or 5 on the Suicidal Ideation item or any "yes" on the Suicidal Behavior item that is related to suicidal behavior occurring during the last 2 years.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use highly effective contraception during the study and for 5 half-lives (14 weeks) after stopping treatment. Highly effective contraception is defined as either:

    1. Total abstinence: When this is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
    2. Sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
    3. Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). [For female study subjects, the vasectomized male partner should be the sole partner for that patient].
    4. Use of a combination of any two of the following (a+b or a+c or b+c):
    1. Use of oral, injected or implanted hormonal methods of contraception.
    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).
    3. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to initial dosing. Menopause will be confirmed by a plasma FSH level of > 40 IU/L (or as determined by the cut off used by the local clinical laboratory) at screening. Female patients who report surgical sterilization must have had the procedure at least six (6) months prior to initial dosing. Surgical sterilization procedures should be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the eCRF. All female patients must have negative pregnancy test results at screening and baseline.

  • Use of oral beta agonists, oral corticosteroids, androgens or androgen inhibitors (including LHRH agonists), or intravenous gamma globulin (IVIG) within the previous 6 months. Short-term corticosteroids for unrelated indications, defined as < 20 mg/d for < 30 days and ending at least 60 days prior to screening, are acceptable.
  • Patients with known bleeding disorders, or who are under treatment with anti-coagulants.
  • A presence or history of clinically relevant ECG abnormalities, or including but not limited to Long QT syndrome, ischemic changes that cannot be shown to be stable for at least 6 months by previous ECG, or 2nd degree Mobitz II or 3rd degree heart block.
  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  • Significant illness which has not resolved within two (2) weeks prior to initial dosing.
  • A positive HIV, Hepatitis B surface antigen or Hepatitis C test result. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02250443


Locations
United States, Arizona
Novartis Investigative Site
Phoenix, Arizona, United States, 85013
United States, Massachusetts
Novartis Investigative Site
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02250443     History of Changes
Other Study ID Numbers: CBYM338X2205E1
First Submitted: March 20, 2014
First Posted: September 26, 2014
Last Update Posted: October 12, 2017
Last Verified: October 2016

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Inclusion Body Myositis (IBM)

Additional relevant MeSH terms:
Myositis
Myositis, Inclusion Body
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Antibodies, Monoclonal
Antibodies, Blocking
Immunologic Factors
Physiological Effects of Drugs